Results 81 to 90 of about 3,663 (172)

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source

Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8⁺ T cell immunity via rewiring MHC-I antigen presentation. [PDF]

Cell Rep Med
Feng H, Zhang Y, Huang Z, Zhou J, Liu Y, Xiao X, Chen M, Guo X, Zheng J, Lyu Z, Hu W, Wu D, Li Y, Xing F.   +13 more
europepmc   +1 more source

Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis. [PDF]

Am J Cardiovasc Drugs
Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.   +8 more
europepmc   +1 more source

Editorial: New drugs in lipid lowering therapy. [PDF]

Front Cardiovasc Med
Bytyçi I, Banach M, Pećin I.
europepmc   +1 more source

Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors. [PDF]

Front Med (Lausanne)
Zhu B, Shao Q, Cui J, Fu Z, Ma Y.
europepmc   +1 more source

Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial. [PDF]

Circulation
Fearon WF, Terada K, Takahashi K, Skoda A, Luikart HI, Lamendola CA, Zimmermann FM, Hashikata T, Saito K, Yoshida A, Varr B, Knowles JW, Woo C, Honda Y, Teuteberg J, Khush KK.   +15 more
europepmc   +1 more source

Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia. [PDF]

J Clin Med
Khattak S, Ochoa-Ferraro A, Khan N, George S, Khan SQ, Townend JN, Dawson C, Thomas MR.   +7 more
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study. [PDF]

Eur Heart J Suppl
Gatto L, Di Bitonto MP, Scalia L, Biccirè FG, Prati F.   +4 more
europepmc   +1 more source

PCSK9 Inhibition Protects Against Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetes Rats Via Suppressing Inflammation and Apoptosis. [PDF]

Anatol J Cardiol
Zhang M, Liu F, Gao Y, He Y, Bian S, Yang B, Liu P, Zheng Y, Zhu Y.   +8 more
europepmc   +1 more source